News
Theranexus to present the results of THN102 for Parkinson’s disease at the 2020 International Congress of Parkinson’s Disease and Movement disorders
Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, will present the Phase II results of its drug candidate THN102...
Amoéba: the efficacy of the biocontrol solution against grapevine downy mildew confirmed through the second European field trials campaign
AMOEBA (FR0011051598 – AMEBA), - producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces that the results of the second field trials campaign...
Field tests confirm the efficacy of Amoeba’s biocontrol solution on several major wheat diseases
AMOEBA (FR0011051598 – AMEBA) - producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the first efficacy results of its biocontrol solution on...
Nosopharm obtains US patent for NOSO-502, a first-in-class novel antibiotic
Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, today announces it has been granted a US patent for NOSO-502. NOSO-502 is Nosopharm’s first clinical candidate in a new class of...
Biocontrol development partnership in France and Europe between AMOEBA, PHILAGRO France and NICHINO Europe
PHILAGRO France, NICHINO Europe and AMOEBA have signed a development contract (MTA: Material Transfer Agreement) to evaluate the performance of the biocontrol fungicide containing AMOEBA's active substance: the amoeba lysate Willaertia magna C2c Maky. Complete press...
C4Diagnostics raises € 2.3 Million in Series A and brings a US investor to the founding round, to accelerate the deployment of its infectious diseases’ diagnostic solutions
The French biotech company, C4Diagnostics®, developing innovative in vitro diagnostic tests in the field of infectious diseases, announces that it has raised € 2.3 million in its Series A funding round led by US private investor Andreï Polukhtin, with the...
Aleva receives CE Mark for the directSTIM TM Deep Brain Stimulation System
Aleva Neurotherapeutics, a leading developer of implants for deep brain stimulation (DBS) in major neurological indications such as Parkinson’s disease and essential tremor, today announced that it has been awarded the CE Mark for its flagship product, the...
AMOÉBA publishes in Scientific Reports, a journal of the Nature Publishing group, the complete genomic analysis of the Willaertia magna C2c Maky amoeba.
AMOÉBA (FR0011051598 - AMEBA), producer of a biological biocide, capable of eliminating bacterial risk in water and human wounds, and a biocontrol product for plant protection, still in the testing phase, announces a major scientific publication. As the result of a...
Diabeloop Completes Record-Breaking European Fundraising Effort With Its Autonomous Diabetes Management Solutions
Diabeloop announced today that it has completed a 31-million-euro Series B round of funding, setting a European fundraising record in the area of therapeutic artificial intelligence.This funding will allow Diabeloop to accelerate its international commercial...
Laclarée raises 2m€ for its seed round with two of the most active Seed investors in France and Germany
Laclarée gets financial support from Kreaxi (France) and HighTech GründerFonds HTGF (Germany) alongside with Bpifrance and a pool of banks. The total amount raised will be 2m€, including non-dilutive financing. Laclarée develops adaptive eyeglasses for presbyopia...